Pre-Eclampsia Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pre-Eclampsia pipeline constitutes 5+ key companies continuously working towards developing 5+ Pre-Eclampsia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Pre-Eclampsia Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pre-Eclampsia Market.

The Pre-Eclampsia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pre-Eclampsia Pipeline Report:
https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pre-Eclampsia treatment therapies with a considerable amount of success over the years.
• Pre-Eclampsia companies working in the treatment market are Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin, and others, are developing therapies for the Pre-Eclampsia treatment
• Emerging Pre-Eclampsia therapies in the different phases of clinical trials are- GMA-312, C 103, CBP-4888, KW-3357, and others are expected to have a significant impact on the Pre-Eclampsia market in the coming years.
• In March 2026, DM199 advanced into a Phase II clinical trial program for early-onset pre-eclampsia after receiving regulatory clearance in Canada, with expansion into the U.S. planned following FDA regulatory approvals. The therapy aims to address the underlying vascular dysfunction associated with pre-eclampsia and represents one of the most advanced disease-modifying candidates in development.
• In December 2025, DiaMedica Therapeutics reported a successful pre-IND meeting with the FDA regarding DM199, an investigational recombinant tissue kallikrein-1 therapy being developed for the treatment of pre-eclampsia. The FDA interaction supported plans for future clinical development in the United States.
• In August 2025, Trinity Biotech announced the launch of its FDA-cleared PreClaraTM Ratio (sFlt-1/PlGF) biomarker test for pre-eclampsia risk assessment following regulatory authorization for commercial deployment in New York State. The test is intended to improve prediction and management of hypertensive disorders during pregnancy.
• In February 2025, The U.S. FDA granted 510(k) clearance to the Roche Elecsys sFlt-1/PlGF ratio test, a prognostic biomarker assay designed to identify hospitalized pregnant women at risk of developing severe pre-eclampsia within two weeks. The test helps clinicians stratify patients into low- and high-risk categories and supports earlier intervention.
• KW-3357 is an antithrombin (AT) medication developed using recombinant DNA technology and precise control over sugar-chain composition. It is a recombinant AT formulation designed to possess an identical amino acid sequence and sugar chain structure as natural human AT.
• In December 2024, Engineers at Penn have achieved a significant breakthrough addressing a major health equity challenge for pregnant individuals affected by pre-eclampsia-a condition caused by inadequate blood flow to the placenta, leading to high maternal blood pressure and limited blood supply to the fetus. Pre-eclampsia is a leading cause of stillbirths and premature births globally, affecting 3 to 5% of pregnancies. Those diagnosed early in pregnancy face increased risks for both themselves and their babies, including serious health complications and potentially fatal outcomes.

Pre-Eclampsia Overview
Pre-eclampsia is a serious pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, most commonly the liver and kidneys. It typically occurs after the 20th week of pregnancy and can affect both the mother and the unborn baby.

Get a Free Sample PDF Report to know more about Pre-Eclampsia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Pre-Eclampsia Drugs Under Different Phases of Clinical Development Include:
• GMA-312: Gmax Biopharm
• C 103: Vicore Pharma
• CBP-4888: Comanche Biopharma
• KW-3357: Kyowa Kirin

Pre-Eclampsia Route of Administration
Pre-Eclampsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pre-Eclampsia Molecule Type
Pre-Eclampsia Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Pre-Eclampsia Pipeline Therapeutics Assessment
• Pre-Eclampsia Assessment by Product Type
• Pre-Eclampsia By Stage and Product Type
• Pre-Eclampsia Assessment by Route of Administration
• Pre-Eclampsia By Stage and Route of Administration
• Pre-Eclampsia Assessment by Molecule Type
• Pre-Eclampsia by Stage and Molecule Type

DelveInsight's Pre-Eclampsia Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pre-Eclampsia product details are provided in the report. Download the Pre-Eclampsia pipeline report to learn more about the emerging Pre-Eclampsia therapies
https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Pre-Eclampsia Therapeutics Market include:
Key companies developing therapies for Pre-Eclampsia are - Kyowa Kirin, Gmax Biopharm, Vicore Pharma, and others.

Pre-Eclampsia Pipeline Analysis:
The Pre-Eclampsia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pre-Eclampsia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pre-Eclampsia Treatment.
• Pre-Eclampsia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pre-Eclampsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pre-Eclampsia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pre-Eclampsia drugs and therapies
https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pre-Eclampsia Pipeline Market Drivers
• Increasing women population suffering from Pre-Eclampsia, growing focus on the development of innovative Pre-Eclampsia diagnostic products are some of the important factors that are fueling the Pre-Eclampsia Market.

Pre-Eclampsia Pipeline Market Barriers
• However, high cost associated with the treatment of Pre-Eclampsia, lack of awareness among patients regarding the disease and other factors are creating obstacles in the Pre-Eclampsia Market growth.

Scope of Pre-Eclampsia Pipeline Drug Insight
• Coverage: Global
• Key Pre-Eclampsia Companies: Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin, and others
• Key Pre-Eclampsia Therapies: GMA-312, C 103, CBP-4888, KW-3357, and others
• Pre-Eclampsia Therapeutic Assessment: Pre-Eclampsia current marketed and Pre-Eclampsia emerging therapies
• Pre-Eclampsia Market Dynamics: Pre-Eclampsia market drivers and Pre-Eclampsia market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.